THE European Medicines Agency
has ordered the withdrawal of
intranasal formulations of
calcitonin for treatment of
osteoporosis, because of evidence
that long-term use of the medicines
is associated with an increased risk
of developing cancer.
Henceforth calcitonin will only be
available as a solution for injection
and infusion in Europe, indicated
for prevention of acute bone loss
due to sudden immobilisation, with
a max four week treatment duration.
It can also be used for Paget’s
disease in patients who do not
respond to alternative treatments,
or hypercalcaemia due to cancer.
“Treatment with calcitonin should
be limited to the shortest possible
time and using the minimum
effective dose,” the EMA said.The above article was sent to subscribers in Pharmacy Daily's issue from 23 Jul 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Jul 12
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.